diabetes add PCSK9 decreases heart probs primary prevention
A very recent study, the VESALIUS-CV (Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke) trial found that adding the PCSK9 inhibitor evolocumab to patients with diabetes with no prior history of ASCVD (atherosclerotic cardiovascular disease) prevented the first major cardiovascular event (see diabetes primary ASCVD prevention with PCSK9 JAMA2026 in dropbox, or doi:10.1001/jama.2026.3277) Details : -- VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab conducted across 774 sites in 33 countries, enrolling 12,257 patients with diabetes but no prior myocardial infarction or stroke, LDL-C level 90mg/dL or greater, and qualifying atherosclerosis or high-risk diabetes. This current study was a prespecified subgroup analysis to examine outcomes in patients without known significant atherosclerosis --none of the patients had prior arterial revascularization, arte...